Professional Media briefs: May 2014

Ivan Oransky
Ivan Oransky

BMJ and the Lupus Foundation of America have published the first articles for Lupus Science & Medicine, which the partners said is the first lupus-specific open-access journal. Lupus Foundation CEO and President Sandra Raymond said in a statement that the foundation's publishing efforts have been scattered across non-lupus publications and that this journal “provides a much needed, centralized home for… lupus research findings.”

MedPage Today's Ivan Oransky's Retraction Watch has launched a subscriber service. Oransky (pictured) and partner Adam Marcus announced the service in a March post, alerting readers that subscriptions to the four-year-old blog would go toward such things as paying writers and creating a database. Funds will be handled by a third party, so as to protect the site's independence.

John Wiley & Sons has updated its 2006 Best Practice Guidelines on Publishing Ethics: A Publisher's Perspective. The goal remains to be a touchstone for advice on what the company calls “the major ethical principles of academic publishing.” The new edition includes guidance about whistle-blowers, clinical trial registration and other subjects.

You must be a registered member of MMM to post a comment.

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters